Nonalcoholic steatohepatitis (NASH) arises from a variable interplay between environmental factors and genetic determinants that cannot be completely replicated in animals. Notwithstanding, preclinical models are needed to understand NASH pathophysiology and test mechanism-based therapies. Among several mouse models of NASH, some exhibit the key pathophysiologic as well as histopathologic criteria for human NASH, whereas others may be useful to address specific questions. Models based on overnutrition with adipose restriction/inflammation and metabolic complications, particularly insulin resistance, may be most useful to investigate critical etiopathogenic factors. In-depth pathologic description is required for all models. Some models demonstrate hepatocyte ballooning, which can be confused with microvesicular steatosis, whereas demonstration of an inflammatory infiltrate and pattern of liver fibrosis compatible with human NASH is desirable in models used for pharmacologic testing. When mice with specific genetic strains or mutations that cause overeating consume a diet enriched with fat, modest amounts of cholesterol, and/ or simple sugars ("Western diet"), they readily develop obesity with liver disease similar to human NASH, including significant fibrosis. Purely dietary models, such as high-fat/high-cholesterol, Western diet, and choline-deficient, amino acid-defined, are similarly promising. We share concern about using models without weight gain, adipose pathology, or insulin resistance/hyperinsulinemia and with inadequate documentation of liver pathology. NASH-related fibrosis is a key endpoint in trials of possible therapies. When studied for this purpose, NASH models should be reproducible and show steatohepatitis (ideally with ballooning) and at least focal bridging fibrosis, while metabolic factors/disordered lipid partitioning should contribute to etiopathogenesis. Because murine models are increasingly used to explore pharmacologic therapies for NASH, we propose a minimum set of requirements that investigators, drug companies, and journals should consider to optimize their translational value. (Hepatology 2019;69:2241-2257).
of noncirrhotic and cirrhotic NASH. (1) NASH is strongly associated with visceral adiposity and adipose inflammation (meta-inflammation), insulin resistance and its important consequence hyperinsulinemia, atherogenic dyslipidemia, and arterial hypertension. (2) Thus, NASH is more closely related to "metabolic obesity" than to body weight. It is clear that genetic (patatin-like phospholipase domain-containing protein 3 [PNPLA3] polymorphisms, family history of type 2 diabetes) as well as environmental factors contribute to individual susceptibility. (3) One concept about how NASH develops is that overnutrition and its metabolic complications primarily favor partitioning of lipid to the liver to cause steatosis, but separate injury-inducing processes are required. Thus, fatty livers exhibit heightened susceptibility to pro-oxidant and endotoxin-induced injury, facilitated by increased intestinal permeability and intestinal "dysbiosis." Available data suggest that the metabolic milieu associated with NASH is directly responsible for inciting hepatocyte injury by a process termed "lipotoxicity." Several lipotoxins have been identified in NASH (reviewed in Marra and Svegliati-Baroni (4) ), and their hepatic accumulation is linked to insulin resistance. Lipotoxic mechanisms with release of danger-activated molecular patterns (DAMPs) and activation of innate immunity to recruit cellular inflammatory responses have been explored. (5, 6) The network of the above interactive factors, potentiating "pathologic insults," has been termed the "multiple hits" concept. Further complexity has been suggested from metabolomic and gene expression studies indicating possible subtypes of human NASH; which may suggest the existence of more than one predominant pathogenic pathway to NASH.
There are many causes of steatohepatitis pathology. In humans these include alcoholic liver disease, Wilson's disease, drug-induced liver injury, and profound weight loss as in jejuno-ileal bypass. When conducting studies in an animal model designed to emulate the metabolic entity of human NASH, it is important to avoid models in which insulin resistance with hyperinsulinemia does not occur, and in which unrelated exogenous factors like alcohol and toxic chemicals or severe dietary macronutrient/micronutrient deprivations causing weight loss occur.
Natural Progression of Steatosis to NASH and Fibrosis/Cirrhosis/HCC
The course of NAFLD in humans follows a variable, nonlinear pattern with phases of progression, nonprogression, and regression along the spectrum toward end-stage liver disease, often over several decades. (7) Added to the slow progression of the disease in subpopulations, this "jigsaw" pattern is difficult to replicate in animal models. Variable degrees of steatosis, hepatocellular injury, and lobular inflammation are necessary preconditions for fibrosis progression but may not all be conspicuous on earlier liver biopsies. (8) It has been estimated that progression of one fibrosis stage every 7 years occurs in the early stages of patients with NASH but that an exponential deposition of scar tissue may occur once fibrosis has advanced beyond stage 2. (9) The main causes of morbidity and mortality in patients with NASH arise from cardiovascular disease and common cancers, but the risks of cirrhotic decompensation and HCC increase steeply with fibrosis stages F3 and F4. For this reason, advanced fibrosis and cirrhosis are now considered the major endpoints in clinical trials of NASH. (7) Because drugs to treat cardiovascular and diabetes comorbidities are on the market, advanced fibrosis and cirrhosis have become the prime indications for regulatory authorities such as the United States Food and Drug Administration and the European Medicines Agency. Importantly, none of the licensed drugs that are used to treat cardiac or metabolic comorbidities, with the possible exception of pioglitazone, have yet been shown to prevent liver fibrosis progression in clinical studies; however long-term studies of agents such as glucagon-like peptide 1 agonists, peroxisome proliferator-activated receptor agonists, and farnesoid X receptor agonists have not yet been reported.
Animal Models of NAFLD and NASH
Since the mid-1990s, investigators have addressed questions about NASH pathogenesis using animal models; the number of published articles increased from ~40/year in 2012 to >100/year in 2017. (10) This review considers only murine models, which now provide a pivotal platform to test therapeutic molecules. (11) (12) (13) In rodents, steatosis is readily induced through provision of excess energy substrates by feeding high-carbohydrate or high-fat diets (HFDs) or in strains with appetite defects that lead to overeating, such as ob/ob (leptin-deficient) or db/db (leptin receptor-mutated) mice (14) or by favoring hepatic lipid sequestration (e.g., with choline-deficient diets or genetic modifications). In the late 1990s, it was shown that a diet deficient in methionine and choline (MCD) caused severe steatohepatitis in rodents, albeit with wasting. (15, 16) Since then, numerous other models with diverse pathogenic mechanisms, metabolic features, histopathology, and disease progression have been evaluated, as summarized in several reviews. (12, 14, (17) (18) (19) (20) (21) In the face of such diversity and the pressing need for "optimal" NASH models for preclinical drug development, it is timely to reflect on appropriate criteria for animal models to mimic human NASH. We do this with some circumspection, noting that the exact models used may be influenced by the precise research question. There may often be advantages in comparing results in more than one model as no model perfectly replicates all of the pathogenic prerequisites for human NASH, which is likely a heterogeneous disorder with differences in detailed pathogenesis.
Human data that dissect disease progression at the cellular and molecular levels are sparse, due to limitations of access to liver tissue. The use of a mouse disease model allows controlled experimental interventions, taking into account multisystem involvement, including neuroendocrine, metabolic, adipose, and immune components. Mouse modeling allows for genetic manipulations, diet, and exercise and for tissue sampling at defined intervals. Preclinical drug testing for efficacy and safety is readily performed. Other advantages of mouse models include relatively short duration of studies (3-6 months) and low cost compared with large animal models. Unlike human phenotyping studies with sampling usually confined to a single time point, an animal model allows the collection of sufficient tissue without sampling error as well as the tracking of physiologic, molecular and cellular dynamics during disease progression or reversal. A mouse model of NAFLD may ideally exhibit the pathological spectrum from steatosis to steatohepatitis (NASH) with fibrosis, and the possible development of HCC, depending on what the model will be used for.
We and others believe that the available evidence supports the proposal that overnutrition causing at least central obesity and insulin resistance (with hyperinsulinemia) defines metabolic predisposition to NASH. If these factors are to be studied experimentally, they can be achieved by several approaches, including the combination of diet and genetic predisposition. Depending on the purpose of the study, a model could replicate some of the metabolic, inflammatory, profibrotic, and hepatocarcinogenic pathways that resemble those documented in human NASH, when known, by metabolomic and tissue studies linked to appropriate liver pathology.
On the other hand, there are inherent disadvantages of using mice to understand human NASH. These include species differences in behavior, nutrient requirements, control of metabolic regulation, coprophagia and the microbiome, immune regulation, the propensity of fibrosis progression to cirrhosis, and the development of HCC as primary outcomes. Unlike humans, mice rarely develop cirrhosis in the absence of repeated toxic insults. Thus, models of progressive NASH will always have "an artificial hue," by having to produce significant disease in a condensed time (3-12 months) compared to the disease course in patients, which evolves over several decades and follows a less predictable course. It is therefore important to consider how far subtle differences in liver pathology, such as failure to develop hepatocyte ballooning, can be accepted in a NASH mouse model. Finally, although some mouse models do not go beyond steatosis without or with mild inflammation, while others develop "fatty liver hepatitis" with significant fibrosis (which we deem to be NASH), it should not be assumed that the underlying pathobiologic mechanisms are the same simply because models and humans arrive at similar pathology. This applies to severe metabolic deficiency as in the MCD diet model or to models with deletion of genes not directly relevant to human NASH.
All mouse experimental models should concur with the Animal Research: Reporting of In Vivo Experiments (ARRIVE) criteria that were recently established by the editors of major biomedical journals. (22) ARRIVE recommends reporting strain/genetic fidelity of animals, use of littermate controls, listing specifics of diet/ nutrients and other elements of humane and healthy animal husbandry, as well as minimization of animal experimentation by limiting this to effective use. Thus, if models are not highly relevant to a research question pertinent to the human disorder, ethical standards of animal experimentation may not be met. We recently reviewed all studies over the last 3 years that employed mouse models claimed to represent NASH (as opposed to NAFLD more broadly) (10) ; of these, only 23% showed overnutrition, 25% showed insulin resistance, alanine aminotransferase (ALT) levels were near normal or not reported in 48% of studies, and liver pathology was assessed by a pathologist with an interest in liver pathology (as required for clinical diagnosis of NASH in humans) in 43%-53% of studies. Many articles failed to report data on body weight during and at the end of experiments, metabolic indices such as blood sugar and serum insulin, and basic analysis of liver injury. (10) Furthermore, in many articles, liver pathology was usually not standardized, or relevant controls were not provided. We are concerned about the scientific validity and translational significance of such studies without use of more stringent characteristics.
What Are We Trying to Achieve?
No current model of NASH can reproduce all of the major features of severe human NASH, including similar patterns of genetic, epigenetic, pathophysiological changes; similar disease course, especially the slow progression to cirrhosis and HCC; and the likely heterogeneity of human NASH. Here, we propose a set of minimum requirements for models of NASH. We particularly emphasize the need for investigators to provide experimental data that allow others to evaluate the model critically.
HIStopatHology
All models of NASH should be fully characterized histologically by a pathologist experienced in evaluating human NASH. (23) Histopathology is the standard of clinical diagnosis and is no less important experimentally. The NAFLD Activity Score (NAS) was developed to facilitate the diagnosis of NASH in humans and to semiquantify changes in disease activity with time and therapeutic interventions. (23) The NAS has been used for these purposes in rodent models, (24, 25) but other scoring systems (such as the steatosis, activity, and fibrosis score) have also been proposed. (26) Of note, hepatocyte ballooning, a component of the NAS, has been suggested as the defining feature of steatohepatitis (Fig. 1) . However, ballooning poses substantive problems for experimental models. Firstly, microvesicular fatty change can be difficult to distinguish from ballooning and is more prominent in mice than in human NASH. Secondly, while in human liver biopsies the rounding up of cells with clearing of the cytoplasm is the defining feature, and thereby distinguishes "classical" from "small cell" ballooning, this has not been specified for rodents. Because in human NASH immunohistochemical (IHC) markers of Mallory-Denk bodies and loss of cytokeratin 8/18 (CK8/18) immunostaining confirm hepatocyte ballooning, (27) we recommend that this approach be explored in mouse models. Likewise, apoptosis is a key feature of NASH liver pathology. We recommend that the use of IHC techniques including terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling, activated caspase 3, and CK18 cleavage products be adopted more widely. (28, 29) In our view, a murine model of NASH is most convincing when unambiguous demonstration and quantification of hepatocyte injury and cell death are documented by one or more of the above methods.
Two histological patterns of NASH are recognized: the more common pattern with predominantly zone 3 pathology and the less common, predominantly portal/periportal inflammation and fibrosis, seen mainly in children. Currently, no mouse model reproduces the latter pattern. Another substantive problem is that the severity of fibrosis in mouse models does not match the full range of changes seen in human NASH (F3 and cirrhosis are rarely seen), unless toxins such as carbon tetrachloride are used. We believe that while additional use of a toxin can accelerate and exacerbate liver fibrosis, which may be useful if one is testing direct antifibrotic agents, the models stop reflecting NASH under these circumstances. We understand and respect that not all workers in the field accept this point of view.
patHogeNIc DeterMINaNtS
Because NASH results from overnutrition, data on body weight, food intake, dietary composition, and energy consumption seem to us to be essential. Organ and tissue weights (especially liver and adipose compartments) should be documented. Insulin resistance is best tested by a dynamic test in addition to static measurements of fasting serum insulin and blood glucose and not simply by molecular signaling assays in isolation. An ideal model may also exhibit other features of the metabolic syndrome, such as diabetes, atherogenic dyslipidemia, and/or arterial hypertension. Because several such models are now available and are no more expensive than MCD dietary models, we would prefer to see their more widespread adoption. Finally, inadequacy of adipose storage of lipid in the face of overnutrition is a likely key determinant of NASH pathogenesis. (30) In models that result from overnutrition, with or without mouse obesity (body weight >40 g), the study of the adipose compartments (visceral and subcutaneous), including assessment of macrophage infiltration and proinflammatory cytokine production, is an important part of model characterization.
geNetIc, epIgeNetIc, aND patHopHySIologIc cHaNgeS
Apart from a few clearly defined genetic drivers, gene expression studies have described varying patterns, suggesting that human NASH is heterogeneous. This could reflect varying sets of predisposing factors and responses to them, resulting in different severity of inflammation and fibrogenesis. Correlations of the liver transcriptome with that of several rodent models have been modest to fair. (31) However, because key processes are often regulated posttranslationally (e.g., hydroxymethylglutaryl-coenzyme A reductase for cholesterol biosynthesis, PNPLA3
I145M for lipid droplet turnover), it may be premature to insist on highly similar transcriptome patterns. On the other hand, epigenetic changes and metabolomics, including analysis of hepatic lipid pools and organelle damage, should be compared with human analyses.
DISeaSe coUrSe
Hepatocyte lipoapoptosis and the resultant inflammation seem likely to represent the primary drivers of fibrogenesis in NASH. Here, the anti-inflammatory immune response dominated by M2-type macrophages (and T helper 2 cells) that follows an acute bout of destructive, M1-type inflammation appears to fuel fibrosis progression. (32) The M2-type immune response is characterized by excess production of transforming growth factor beta 1 (TGF-β1) and interleukin 13 (IL-13), two central profibrogenic mediators. (32, 33) This is in agreement with the low-grade chronic (meta-) inflammation that underlies disease progression in NAFLD and its extrahepatic manifestations, such as adipose tissue inflammation. (34) Moreover, mitochondrial dysfunction as well as oxidative and other cellular stresses central to hepatocellular injury and cell death (5) should be considered in relevant models.
The complexity of the clinical course and pathophysiology, involving the liver, adipose tissues, the vascular system, insulin regulation, the intestine, and the intestinal microbiome, "raises the bar" for a representative NASH model, as does the individual variability in the human disease discussed earlier. Clinical NASH can progress, remain constant, or regress with changes in weight due to nutrition and exercise and possibly other ill-defined environmental factors. (8) Therefore, models of progressive NASH, having to produce significant disease in a condensed time, will never be fully commensurate with advanced human disease, which evolves over decades.
Types of NASH Models
Selection of a model depends partly on the question addressed. NASH models are broadly characterized as dietary, genetic, or toxic; and many incorporate a combination of etiopathogenic factors. Whatever the model, "background data" such as body weight, tissue weights including adipose tissue, insulin resistance, circulating metabolites (fasting blood glucose, serum lipids), injury (serum ALT), histological grading, and staging with quantitative morphometry of inflammation and fibrosis are required for every study.
DIetary MoDelS
These are summarized in Table 1 , and original references are cited in several reviews. (10, 12, 14, (17) (18) (19) (20) (21) 35, 36) Overnutrition can be obtained by use of HFDs, but in most strains of mice body weights exceeding 40 g (obese for mice) are not achieved. Further, neither pure high-fat nor high-carbohydrate diets lead to NASH. (17, 37) More successful dietary strategies incorporate a surplus of cholesterol and fructose to a high-fat, high-carbohydrate diet or add trans-fats; such diets are referred to as "atherogenic" (our preferred term) or "Western diet," "fast-food diet," or high-fat plus high-cholesterol diet. (17, 37) As an excellent example of this, the "Western diet" described by Charlton and colleagues leads to overnutrition, adipose pathology, insulin resistance, and steatohepatitis pathology with fibrosis after 6 months. (38) The cholesterol content of such diets varies from 0.1% (wt/wt) (as in the diet-induced animal model of NAFLD [DIAMOND] mice (39) ) to 2% (37) ; ~0.2% is most commonly used and is still high for a rodent. Very high cholesterol content (>0.5%) is undesirable, being toxic and far above human consumption. (40) Several studies refer to an HFD containing lard or milk fat; these crude preparations contain significant cholesterol, despite the statement that "no cholesterol was added" (for original reference, see Haczeyni et al. (10) ). We strongly recommend that details of nutrients in any diet administered be provided.
The MCD model was adopted by two of us (I.L., G.F.) in year 2000 as one of the first to show steatohepatitis histology. (15, 16) For its simplicity and short duration, this model is still the most commonly used (42% of articles between 2015 and 2017 (10) ). We showed that it usually takes 3 weeks to develop unequivocal steatohepatitis and 5 weeks for appreciable fibrosis, (15, 41) making the MCD model one of the most rapid for developing visible liver fibrosis. Unfavorably, by 8 weeks mice have lost ~40% of their weight, most likely because of a hypermetabolic state. There is no residual adipose tissue, and they display peripheral insulin sensitivity with low serum insulin levels, despite biochemical evidence of hepatic insulin resistance. (17, 41, 42) Moreover, hepatocyte ballooning is not seen, and Mallory-Denk bodies are absent. Gores et al. have stated, "use of the MCD diet is far from optimal to examine metabolic parameters of NAFLD and its use should be discouraged." (17) We agree with this well-reasoned point of view, since a relatively large number of more satisfactory alternatives are available at similar cost to investigators.
To overcome weight loss and insulin sensitivity, the MCD model has been combined with an HFD and/or a high-sucrose diet or genetically obese-prone strains such as db/db mice, which are insulin-resistant due to altered leptin signaling. Another useful adaptation is the choline-deficient, amino acid-defined (CDAA) diet in which sulfhydryl-containing amino acids are less restricted and ample energy is supplied by an HFD, often with 0.2% cholesterol. The HFD-CDAA model induces weight gain, steatohepatitis (with mild ballooning), and 3-fold increased liver collagen after 12 weeks, (43) with progression to advanced-stage fibrosis and HCC beyond 30 weeks. (44) Modest insulin resistance (by homeostatic model assessment for insulin resistance) was shown in two studies (43, 45) and occurred similarly in choline-supplemented, amino acid-defined controls. While more metabolic and immunological studies are needed, the histopathological changes (Fig. 1 ) suggest that this model is All of these models are described in several excellent recent reviews (12, 14, 17, (19) (20) (21) ; for original articles describing these models, we refer readers to these reviews and to Krishnan et al.,
Idrissova et al., (36) and Charlton et al. (38) Abbreviations: CDAA, choline-deficient, amino acid-defined; CSAA, choline-supplemented, amino acid-defined; HFD, High fat diet; HFHC, high-fat and high-cholesterol diet;
MCD, methionine and choline-deficient. 
geNetIc MoDelS
Genetic models of NASH are summarized in Table 2 and described in detail in several reviews. (10, 12, 14, (17) (18) (19) (20) (21) Voluntary overeating occurs in mice with single mutations of appetite-regulating genes, especially ob/ob (leptin-deficient), db/db (deficient leptin signaling), foz/foz (spontaneous mutations in the Alström syndrome 1 gene, which encodes a protein localized to centrosomes and appetite-sensing neuronal cilia), and melanocortin receptor 4 knockout (Mc4r -/-) mice resembling obesity in humans. This contrasts with human NASH, which usually occurs in the context of multifactorial obesity in which various single-nucleotide polymorphisms, epigenetic modifications, and environmental factors drive excess energy consumption. With such models, a balanced diet leads to steatosis, while an atherogenic diet is needed to produce NASH. Thus, these models differ from dietary models in normal strains by their greater extent of obesity and propensity for the metabolic complications found in human NASH.
In three genetic models (atherogenic diet-fed foz/foz, (24, 25) DIAMOND, (39) and Mcr4 -/-(46) mice) liver pathology has been reviewed by experienced liver pathologists and meets the histological criteria of human NASH. The foz/foz model has been reproduced in several laboratories (24, 25) and shows typical steatohepatitis pathology with macrovesicular steatosis, hepatocyte ballooning, and apoptosis, with M30-positive hepatocytes reflecting CK8/18 cleavage by caspase 3. (25) Lobular inflammation with formation of crown-like structures of macrophages surrounding lipid-laden hepatocytes (11, 24) is severe at 16-24 weeks of atherogenic dietary feeding (Fig. 2) , with typical NAS scores of 6-8. (11, 24, 25) The extent of fibrosis (generally stage 1-2) depends on strain and feeding duration. Therefore, the foz/foz model has been employed as a NASH mouse model with obesity to study potential therapeutic interventions. (12) Mc4r -/-mice likewise show obesity-related insulin resistance, adipose tissue inflammation, and liver histologic features diagnostic for human NASH. (46) Mouse strains vary in proclivity to develop insulin resistance, which is pronounced in nonobese diabetic NOD.B10 mice (while, for example, the Balb/c line is resistant), diabetes, and liver fibrosis. For this reason, the genetic background of mouse strains has to be clearly characterized. The details required include strains and substrains and number of generations since revitalizing stock. Such information has not been reported for DIAMOND mice, which have a mixed background (129S1/SvlmJ × C57Bl/6J), generated by brother-sister matings over 4 years. (39) These mice develop NASH when fed an atherogenic diet containing 0.1% cholesterol with sucrose and fructose added to drinking water (Table 2) , with insulin resistance, hepatocyte ballooning, and perivenular/pericellular fibrosis in zone 3, reaching stage F2-F3 after 52 weeks, and HCC in male mice. Here, as in human NASH, features of ballooning (Fig. 1) include loss of CK18 immunostaining (28, 29) and Mallory-Denk bodies. (39) Other monogenetic models have been used to test the role of particular metabolic pathways in NASH pathogenesis. These include mice with defects of hepatic cholesterol transport (lysophospholipid receptor knockout and apolipoprotein E knockout mice), insulin receptor signaling (phosphatase and tensin homolog knockout), fat synthesis, and triglyceride transport (sterol regulatory element-binding protein 1c knockout and microsomal triglyceride transfer protein knockout, see Table 2 for details). As for all genetic models, dietary composition remains important. Generally, HFDs with added cholesterol, often with fructose as well, are needed to produce liver inflammation and some degree of fibrosis. The applicability of these models is to study the metabolic pathways of interest, for example, detailed studies on cholesterol turnover.
toXIcIty MoDelS
Steatohepatitis occurring as a drug-induced liver disease clearly differs in etiopathogenesis from metabolic NASH. In this vein, the use of hepatotoxic chemicals such as the addition of carbon tetrachloride to study fibrosing NASH is likely to represent the effects of the toxin more than metabolic liver disease, which we regard as NASH.
Another attempt to model NASH has been to use a low, nonhepatotoxic dose of streptozotocin to destroy pancreatic beta cells, the streptozotocin-treated neonatal mice on HFD (STAM) mouse. (47) Most reports have been based on evaluations by the commercial provider. Steatosis develops in 5-6 weeks, steatohepatitis in 7-8 weeks, and mild fibrosis at 9-12 weeks. From an expert pathologist perspective (M.M.Y., R.G.), "microvesicular" steatosis but no ballooning is evident in this model, and mild zone 3 perivenular/pericellular fibrosis develops, thus not reflecting human NASH. Importantly, STAM mice do not display insulin resistance and resultant hyperinsulinemia but rather show insulin deficiency. Because hyperinsulinemia resulting from insulin resistance is a likely pathogenic driver of NASH, we suggest that this model should not be used.
Models That Replicate Liver Fibrosis in NASH
As outlined previously, the best preclinical fibrosis models for antifibrotic drug testing include improved standardized models of toxin-induced fibrosis, especially fibrosis reversibility after toxin discontinuation, coupled with models of biliary fibrosis, such as the multidrug resistance 2 knockout mouse. (48) While rapid progress is being made with direct-acting antifibrotic therapies, these therapies are not yet in clinical trials. Therapeutic strategies in NASH may achieve antifibrotic effects indirectly, by reducing liver cell injury and inflammatory recruitment. Only this aspect is considered here because it requires robust models of NASH fibrosis.
Histological staging does not correlate well with absolute amounts of fibrosis. Fibrosis severity is best assessed by the evaluation of parenchymal architecture and quantification of accumulated scar matrix. (48) This evaluation is best done by collagen morphometry on sirius red-stained sections, allowing quantification of collagen area, possibly refined by immune staining for specific extracellular matrix (ECM) proteins. Total collagen should also be assessed by biochemical quantification of hydroxyproline, though this does not differentiate between portal and parenchymal collagen accumulations, which have variant functional consequences. In contrast, sirius red morphometry needs to be done in at least five high-power fields and should be performed separately for portal versus parenchymal collagen. Sirius red morphometry and hydroxyproline both provide continuous data. Approaches to establish whether matrix deposition is more active than resolution are also desirable. These include quantification of a subfraction of ECM-producing, alpha-smooth muscle actin-positive myofibroblasts and changes in expression of profibrogenic transcripts that encode, for example, procollagen α1(I), TGF-β1, tissue inhibitor of matrix proteinase 1, and integrin β6 or of putatively fibrolytic genes such as those encoding matrix metalloproteinases 9 and 13. (48) A thorough analysis would include quantitative immunohistochemistry and/or fluorescence-activated cell sorting (FACS) FIg. 3 . Schematic representation of pathogenic mechanisms linking lipotoxicity to chronic hepatocellular injury, inflammation, fibrosis, and, eventually, end-stage liver disease. The metabolic milieu associated with NASH is directly responsible for inciting hepatocyte injury and liver inflammation by the process termed "lipotoxicity." Several lipotoxins have been identified in NASH but not in simple steatosis. Their hepatic accumulation is linked to insulin resistance and hyperinsulinemia. Hepatocyte lipoapoptosis and lipotoxic mechanisms with release of DAMPs and activation of innate immunity to recruit cellular inflammatory responses appear to be the primary drivers of fibrogenesis in NASH. Here, the anti-inflammatory immune response dominated by M2-type macrophages (and T helper 2 cells) that follows an acute bout of destructive, M1-type inflammation appears to fuel fibrosis progression. The M2-type immune response is characterized by excess production of TGF-β1 and IL-13, two central profibrogenic mediators. Decreased production of certain matrix metalloproteinases, together with an excess of their inhibitors (tissue inhibitors of metalloproteinases) further favors fibrosis progression. Lipotoxicity and the resultant hepatocellular injury, immune alterations, and fibrosis, if perpetuated, eventually lead to cirrhosis and emergence of HCC. Abbreviations: FFA, free fatty acid; HBV, hepatitis B virus; HCV, hepatitis C virus; MMP, matrix metalloproteinase; ROS, reactive oxygen species; T2D, type 2 diabetes; TIMP, tissue inhibitor of metalloproteinase; TLR4, Toll-like receptor 4. 
Weight loss can lead to resolution of NASH, in both humans and rodents. NASH resolves in 90% of patients who lose 10% of body weight by lifestyle intervention, and this is associated with improvement of liver fibrosis in 45% of patients. (50) This strongly supports the central role that overnutrition and metabolic factors play in the pathogenesis of fibrotic NASH. It is important therefore to control for drug-induced weight loss in rodent models of NASH, for example, with agents like glucagon-like peptide 1 agonists and obeticholic acid. (51) A pathophysiological schema on factors contributing to fibrogenesis is presented in Fig. 3 . Taken together, a primary requirement for a NASH model to evaluate fibrosis is to recapitulate the metabolic, lipotoxic, and proinflammatory environment in which NASH occurs, as well as the key hepatocyte processes of cell injury and death. Given the limitations of any one model, demonstrating a reproducible effect in more than one model may provide more powerful evidence of drug efficacy.
Conclusions and Future Directions
We recommend that for preclinical drug testing aimed at reversing NASH, the mouse models used should exhibit weight gain, abnormal lipid distribution (or adipose dysfunction/inflammation), and insulin resistance resulting in hyperinsulinemia (Table 3) . Ideally, more than one model should be used to test key observations. Details about dietary composition and genetic strain details should be included, and it is vital that the liver pathology be reviewed by a pathologist with experience in human NASH. While the severity of ballooning (if present), inflammation, and fibrosis can be conveniently scored by a system in use for clinical NASH, continuous variables pertinent to these factors are more optimal in animal studies. Specific immunostaining approaches to clarify possible hepatocyte ballooning and apoptosis should be used more widely, but there is not yet agreement in the field on whether models that fail to develop ballooning are valid for the study of NASH. We strongly recommend that fibrosis should be quantified by morphometry and hydroxyproline determination and that inflammatory cell subsets should be assessed by quantitative IHC and/or FACS analysis. Some models in current use are associated with weight loss and insulin sensitivity. We do not favor their use, nor can we condone use of toxins to promote fibrosis in a NASH model, which in our view should always be based on metabolic changes. There are now several models of steatohepatitis related to overnutrition with adipose tissue inflammation/dysfunction, insulin resistance, and other features of the metabolic syndrome and well-documented liver pathology that fully replicates human NASH. Their further exploration and reproducibility in other laboratories are awaited with interest as a major advance in this field. Future studies 
